Literature DB >> 21643792

Kynurenines and headache.

Arpád Párdutz1, Annamária Fejes, Zsuzsanna Bohár, Lilla Tar, József Toldi, László Vécsei.   

Abstract

In parallel to serotonin synthesis, the major route of tryptophan catabolism is the kynurenine pathway, which produces neuroactive metabolites. Among these substances, kynurenic acid has potential neuroprotective action blocking glutamate release and glutamatergic neurotransmission. Glutamate is a key player in migraine pathogenesis; it is crucial in the communication of first and second-order neurons, and it has an important role in the genesis of cortical spreading depression, which is the electrophysiological correlate for migraine aura and may be involved in the activation of the trigeminal system. Thus, kynurenines may affect the pathogenesis directly, by acting on glutamate receptors and exerting other neuromodulatory effects, and indirectly via an altered serotonin metabolism. This work summarizes our current results regarding the role of the kynurenine system in trigeminal activation and other events occurring during migraine headache.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21643792     DOI: 10.1007/s00702-011-0665-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  172 in total

Review 1.  Antioxidant properties of indole-3-pyruvic acid.

Authors:  V Politi; S D'Alessio; G Di Stazio; G De Luca
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

2.  Brain stem activation in spontaneous human migraine attacks.

Authors:  C Weiller; A May; V Limmroth; M Jüptner; H Kaube; R V Schayck; H H Coenen; H C Diener
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

3.  Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients.

Authors:  P Martelletti; G Stirparo; S Morrone; C Rinaldi; M Giacovazzo
Journal:  J Mol Med (Berl)       Date:  1997-06       Impact factor: 4.599

4.  IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.

Authors:  G J Guillemin; S J Kerr; L A Pemberton; D G Smith; G A Smythe; P J Armati; B J Brew
Journal:  J Interferon Cytokine Res       Date:  2001-12       Impact factor: 2.607

5.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

6.  Immunological aspects in migraine: increase of IL-10 plasma levels during attack.

Authors:  I Munno; M Marinaro; A Bassi; M A Cassiano; V Causarano; V Centonze
Journal:  Headache       Date:  2001-09       Impact factor: 5.887

7.  A nosographic analysis of the migraine aura in a general population.

Authors:  M B Russell; J Olesen
Journal:  Brain       Date:  1996-04       Impact factor: 13.501

8.  Spinal cord morphology and antinociception after chronic intrathecal administration of excitatory amino acid antagonists in the rat.

Authors:  Jens D Kristensen; Claes Post; Torsten Gordh; Björn A Svensson
Journal:  Pain       Date:  1993-09       Impact factor: 6.961

9.  Differential effects of NMDA and non-NMDA receptor antagonists on spinal cutaneous vs muscular nociception in the cat.

Authors:  X J Song; Z Q Zhao
Journal:  Neuroreport       Date:  1993-01       Impact factor: 1.837

10.  The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis.

Authors:  D D Mitsikostas; M Sanchez del Rio; C Waeber; M A Moskowitz; F M Cutrer
Journal:  Pain       Date:  1998-05       Impact factor: 6.961

View more
  10 in total

1.  Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex.

Authors:  Annamária Fejes-Szabó; Zsuzsanna Bohár; Enikő Vámos; Gábor Nagy-Grócz; Lilla Tar; Gábor Veres; Dénes Zádori; Márton Szentirmai; János Tajti; István Szatmári; Ferenc Fülöp; József Toldi; Árpád Párdutz; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2014-01-03       Impact factor: 3.575

Review 2.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

Review 3.  Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important.

Authors:  Martina Curto; Luana Lionetto; Francesco Fazio; Dimos-Dimitrios Mitsikostas; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2015-02-24       Impact factor: 3.397

4.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Authors:  Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2016-09-14       Impact factor: 3.575

5.  Kynurenines and other novel therapeutic strategies in the treatment of dementia.

Authors:  Zsófia Majláth; János Tajti; László Vécsei
Journal:  Ther Adv Neurol Disord       Date:  2013-11       Impact factor: 6.570

6.  Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund's adjuvant model of orofacial pain.

Authors:  Edina K Cseh; Gábor Veres; Tamás Körtési; Helga Polyák; Nikolett Nánási; János Tajti; Árpád Párdutz; Péter Klivényi; László Vécsei; Dénes Zádori
Journal:  J Headache Pain       Date:  2020-04-21       Impact factor: 7.277

7.  A Possible Role of Amyloidogenic Blood Clotting in the Evolving Haemodynamics of Female Migraine-With-Aura: Results From a Pilot Study.

Authors:  Sulette de Villiers; Janette Bester; Douglas B Kell; Etheresia Pretorius
Journal:  Front Neurol       Date:  2019-11-26       Impact factor: 4.003

8.  SZR-104, a Novel Kynurenic Acid Analogue with High Permeability through the Blood-Brain Barrier.

Authors:  Kinga Molnár; Bálint Lőrinczi; Csilla Fazakas; István Szatmári; Ferenc Fülöp; Noémi Kmetykó; Róbert Berkecz; István Ilisz; István A Krizbai; Imola Wilhelm; László Vécsei
Journal:  Pharmaceutics       Date:  2021-01-05       Impact factor: 6.321

9.  KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion.

Authors:  M Lukács; K Warfvinge; L S Kruse; J Tajti; F Fülöp; J Toldi; L Vécsei; L Edvinsson
Journal:  J Headache Pain       Date:  2016-07-05       Impact factor: 7.277

10.  Kynurenic Acid Inhibits the Electrical Stimulation Induced Elevated Pituitary Adenylate Cyclase-Activating Polypeptide Expression in the TNC.

Authors:  Tamás Körtési; Bernadett Tuka; János Tajti; Teréz Bagoly; Ferenc Fülöp; Zsuzsanna Helyes; László Vécsei
Journal:  Front Neurol       Date:  2018-01-16       Impact factor: 4.003

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.